Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pepgen Inc (PEPG)

Pepgen Inc (PEPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 120,260
  • Shares Outstanding, K 69,115
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,660 K
  • EBIT $ -94 M
  • EBITDA $ -91 M
  • 60-Month Beta 2.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.83

Options Overview Details

View History
  • Implied Volatility 169.02% (-2.81%)
  • Historical Volatility 259.69%
  • IV Percentile 19%
  • IV Rank 17.08%
  • IV High 828.50% on 09/17/25
  • IV Low 33.17% on 09/05/25
  • Expected Move (DTE 15) 0.3655 (20.77%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 45
  • Volume Avg (30-Day) 724
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 13,735
  • Open Int (30-Day) 9,097
  • Expected Range 1.3945 to 2.1255

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 5
  • High Estimate $-0.27
  • Low Estimate $-0.44
  • Prior Year $-0.92
  • Growth Rate Est. (year over year) +66.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3200 +33.33%
on 03/31/26
6.7800 -74.04%
on 03/04/26
-4.7700 (-73.05%)
since 03/02/26
3-Month
1.3200 +33.33%
on 03/31/26
7.5000 -76.53%
on 01/07/26
-5.4100 (-75.45%)
since 01/02/26
52-Week
0.8801 +99.98%
on 04/09/25
7.8000 -77.44%
on 01/02/26
+0.3000 (+20.55%)
since 04/02/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG). Such investors are advised to contact...

PEPG : 1.7700 (+1.72%)
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed...

PEPG : 1.7700 (+1.72%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG).  Such investors are advised to contact...

PEPG : 1.7700 (+1.72%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG).  Such investors are advised to contact...

PEPG : 1.7700 (+1.72%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG).  Such investors are advised to contact...

PEPG : 1.7700 (+1.72%)
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

– FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 – – Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected...

PEPG : 1.7700 (+1.72%)
PepGen Announces Regulatory Updates on FREEDOM2

- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and...

PEPG : 1.7700 (+1.72%)
PepGen to Participate in the Leerink Global Healthcare Conference

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 1.7700 (+1.72%)
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 1.7700 (+1.72%)
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 1.7700 (+1.72%)

Business Summary

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 2.2467
2nd Resistance Point 2.1133
1st Resistance Point 1.9267
Last Price 1.7700
1st Support Level 1.6067
2nd Support Level 1.4733
3rd Support Level 1.2867

See More

52-Week High 7.8000
Fibonacci 61.8% 5.1566
Fibonacci 50% 4.3401
Fibonacci 38.2% 3.5235
Last Price 1.7700
52-Week Low 0.8801

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.